Skip to main content

Table 4 Clinical findings related to ELABELA levels in patients with CLL

From: Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?

VariablesStudy populationCLL
ELABELAELABELA
rprp
Disease duration−0.1530.332
Stage−0.2460.116
Haemoglobin0.0500.6550.0870.582
WBC0.3570.001*0.0870.585
Neutrophil0.0910.4110.0510.748
Lymphocyte0.3620.001*0.0680.667
Platelet−0.2020.067−0.0410.797
  1. r = Spearman’s correlation coefficient
  2. Abbreviations: WBC White blood cell